|Bid||13.41 x 900|
|Ask||13.46 x 900|
|Day's Range||12.17 - 13.68|
|52 Week Range||12.07 - 36.49|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.67|
SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ™, will present a corporate overview at the upcoming virtual H.C. Wainwright Global Life Sciences Conference. The presentation will be available through the virtual conference portal on Tuesday, March 9, 2021 at 7:00 am EST. The team is also taking individual meetings at the event.
SQZ Biotechnologies (NYSE: SQZ) fell by nearly 16% on Friday following the company's announcement of a new funding round. SQZ (pronounced "squeeze") is issuing 3 million new shares of common stock in an underwritten public offering that was priced Friday at $20 per share. As is customary in secondary stock flotations, SQZ's underwriters have been granted a 30-day option to purchase extra stock.
SQZ Biotechnologies Co (NYSE: SQZ) prices its underwritten public offering of 3 million common shares at $20 per share. Underwriters have an option to purchase up to an additional 450,000 shares. The offer price represents a discount of 9% on the last close of $22 on Thursday. The offering is expected to close on February 17. BofA Securities, Evercore ISI, and Stifel are acting as joint book-running managers for the offering. BTIG is acting as the lead manager for the offering. The FDA recently signed off the company's Investigational New Drug application for SQZ Activating Antigen Carriers in HPV+ tumors. The trial will investigate SQZ-AAC-HPV, a cell therapy candidate generated from red blood cells engineered with tumor-specific antigens. This trial marks the first clinical program from the company's SQZ AAC platform. Price Action: SQZ stock dropped 17.7% at $18.12 in the market trading hours on the last check Friday. See more from BenzingaClick here for options trades from BenzingaCorvus Pharma Shares Drop After M Equity Raise At 11% DiscountOncorus Secures M Via Equity At 9% Discount© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.